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In vitro uptake of recombinant factor VIIa by megakaryocytes
with subsequent production of platelets containing
functionally active drug
Recombinant activated factor VII (rFVIIa) has been
recently shown to prevent spontaneous bleeding in inhibitor-
complicated haemophilia when administered once daily
(Konkle et al, 2007; Young et al, 2012). The pro-haemostatic
effect of rFVIIa prophylaxis is difficult to explain given its
plasma half-life of 2 h.
In the literature, four mechanisms explaining the prophy-
lactic efficacy of once-daily rFVIIa administration have been
proposed, including the requirement of much lower doses of
rFVIIa to prevent than to treat bleeding, improvement of
endothelial cell permeability, uptake of rFVIIa by platelets,
and redistribution of rFVIIa into the extravascular space (Lis-
man & de Groot, 2015). Accumulation of rFVIIa in bone
and joints may explain the prophylactic activity of rFVIIa.
One study suggested that rFVIIa was taken up by megakary-
ocytes within the bone marrow (Gopalakrishnan et al, 2010).
The present study tested the hypothesis that megakary-
ocytes that have taken up rFVIIa will produce rFVIIa-con-
taining platelets, which may explain the prolonged
haemostatic effect of rFVIIa in a prophylactic setting.
We used the megakaryoblastic cell line MEG-01, which
was cultured and differentiated by valproic acid as described
earlier (Kirschbaum et al, 2015). After at least 10 d of differ-
entiation, different concentrations of rFVIIa were added to
the culture medium and after 2 h, MEG-01 cells were either
harvested or stimulated to produce platelet-like particles
(PLPs) by addition of 100 ng/ml recombinant human throm-
bopoietin (rTHPO; Life Technologies, Carlsbad, CA, USA)
for 3 d. Cells or PLPs were harvested by centrifugation,
washed and lysed by freeze-thawing the samples twice.
We first showed that rFVIIa was dose-dependently taken
up by MEG-01 cells (Fig 1A). After 3 d of rTHPO stimula-
tion, hardly any rFVIIa was detected in the MEG-01 cells
(Fig 1B). In contrast, the PLPs produced from these MEG-01
cells contained appreciable amounts of rFVIIa (Fig 1C),
which suggests rFVIIa is selectively transferred to PLPs.
Active selection of agents to be transferred to platelets in the
process of megakaryocyte maturation has been previously
demonstrated, as megakaryocytes transfer some, but not all,
mRNA species examined to platelets (Cecchetti et al, 2011).
Fig 1. Dose-dependent uptake of rFVIIa by MEG-01 cells with subsequent production of PLPs containing functionally active rFVIIa. (A–C)
rFVIIa was added in different concentrations (0–100 nmol/l) to valproic acid-stimulated MEG-01 cells, which were harvested after 2 h (A), or
stimulated with 100 ng/ml recombinant human thrombopoietin to produce platelet-like particles (PLPs). After 3 d, MEG-01 cells (B) or PLPs
(C) were isolated by centrifugation. Lysates of MEG-01 cells and PLPs were tested for rFVIIa content using a microtitre plate-based clotting assay
in factor VII-depleted plasma as previously described (Schut et al, 2014), and rFVIIa levels in the lysates were expressed relative to the total pro-
tein content of these lysates (Pierce BCA protein assay kit, Thermo Scientific, Hanover Park, IL, USA). A calibration curve of rFVIIa was used to
convert clotting times to rFVIIa concentrations. Shown are means of 3 independent experiments, error bars indicate standard error of mean
(SEM). (D) Immunofluorescent stains of MEG-01 cells (i–iii) or PLPs (iv) using an antibody to factor VII(a). Shown are typical examples of
MEG-1 cells that were exposed to 100 nmol/l rFVIIa for 2 h (i) or 3 d (iii) or cells that were exposed for 2 h to vehicle (ii). In addition, PLPs
derived from MEG-01 cells exposed to 100 nmol/l of rFVIIa harvested at day 3 are shown (iv). Cells were permeabilized with 01% (v/v) triton
X-100 in phosphate-buffered saline (PBS) for 10 min at room temperature, and stained with 5 lg/ml monoclonal mouse anti-human FVII fol-
lowed by 5 lg/ml Alexa Fluor 488 goat anti-mouse antibody and counterstained with 4 units/ml Alexa Fluor 594 phalloidin (A12381; Life Tech-
nologies, Carlsbad, CA, USA). This staining was used to indicate the cell membrane, but for clarity the staining itself is not shown in the figures.
All samples were fixed using Vectashield Hardset mounting medium with DAPI (Vector Laboratories Inc. Burlingame, CA, USA). rFVIIa is
stained in green, nuclei in blue, and the cell membrane is represented by the dotted line. Scale bars represent 20 lm (MEG-01 cells) or 10 lm
(PLPs). Original magnification 10009. (E) Flow cytometry analysis of PLPs derived from MEG-01 cells that have been exposed to 100 nmol/l of
rFVIIa using permeabilized (green line) or non-permeabilized (blue line) cells. The black line represents PLPs generated from MEG-01 cells that
not have been exposed to rFVIIa. PLPs were fixed with 2% (v/v) formaldehyde in 09% NaCl for 10 min at room temperature and permeabilized
with 01% (v/v) triton X-100 in PBS or vehicle for 10 min at room temperature. After washing, samples were stained for rFVIIa using 10 lg/ml
monoclonal mouse anti-human FVII [ABIN951602, clone AA-3, antibodies-online, Germany (www.antikoerper-online.de)] for 1 h at room tem-
perature followed by 10 lg/ml Alexa Fluor 488-labelled goat anti-mouse antibody (A-11001; Life Technologies) for 30 min at room temperature.
Data shown is representative of three independent experiments. (F, G) PLPs derived from MEG-01 cells exposed to 100 nmol/l rFVIIa or vehicle
were added to normal pool plasma (NPP), factor VII or factor VIII depleted plasma at a final concentration of 10 000 PLPs/ll plasma, and tested
by calibrated automated thrombography using the platelet-rich plasma (PRP) reagent (Thrombinoscope BV, Maastricht, The Netherlands). Shown
are lag time (F) values derived from thrombin generation curves and representative thrombin generation curves (G). Data represent the mean of
three independent experiments. Error bars indicate standard deviation. *P < 005, **P < 001, ***P < 0001 by paired t-test. def., deficient.
482 ª 2016 John Wiley & Sons Ltd
British Journal of Haematology, 2017, 178, 476–491
Correspondence
(A)
(D)
i ii
iii iv
(F)
(G)
(E)
(B) (C)
ª 2016 John Wiley & Sons Ltd 483
British Journal of Haematology, 2017, 178, 476–491
Correspondence
To confirm that rFVIIa is taken up by MEG-01 cells (and
not just associated with the cell), we stained MEG-01 cells or
PLPs for rFVIIa and examined cells using fluorescence
microscopy. There was an ubiquitous presence of rFVIIa
within the vast majority of cells (80–90%) in an apparent
punctuate pattern at 2 h after the addition of rFVIIa to the
culture medium (Fig 1D i), whereas no staining was detected
in cells that had not been exposed to rFVIIa (Fig 1D ii).
After 3 d of rTHPO stimulation, no rFVIIa staining was
detected in the MEG-01 cells (Fig 1D iii). The MEG-01 cell-
derived PLPs harvested at day 3, however, did stain positive
for rFVIIa (Fig 1D iv). We also used flow cytometry to
confirm the presence of rFVIIa within PLPs. rFVIIa was pre-
dominantly localized within the PLP because 556%  113%
[mean  SD, n = 3] of permeabilized cells stained positive
for rFVIIa, compared to 199%  51% [mean  SD, n = 3]
of non-permeabilized cells (Fig 1E).
rFVIIa within PLPs is haemostatically active, as levels were
determined in PLP lysates with a functional coagulation
assay. To determine whether this functionally active rFVIIa
contributes to haemostasis in a plasma environment, we per-
formed in vitro thrombin generation measurements using
plasma to which intact PLPs were added. Addition of
rFVIIa-containing PLPs resulted in a profound shortening of
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Fig 2. rFVIIa uptake by MEG-01 cells is mediated by endothelial protein C receptor (EPCR). (A, B) MEG-01 cells were stained for glycoprotein Iba
(A) using 156 lg/ml R-Phycoerythrin (PE)-labelled monoclonal mouse anti-human CD42b (GPIb, clone AN51, Dako Denmark, Glostrup, Den-
mark) or EPCR (B) using 10 lg/ml R-PE-labelled rat anti-human CD201 antibody (EPCR, clone RCR-401, Biolegend, San diego, CA, USA) for
20 min at 37°C and analysed by flow cytometry. The black lines represent the background fluorescence of the MEG-01 cells, and the blue lines corre-
spond to appropriate isotype controls. Data shown is representative of three independent experiments. (C) MEG-01 cells were incubated with
100 nmol/l of rFVIIa for 2 h in presence or absence of 30 lg/ml Annexin V (AnnV) or 45 lg/ml rat monoclonal anti-EPCR antibody (RCR-252;
Novus Biologicals, Littleton, CO, USA), and rFVIIa content of cell lysates was determined by a microtitre plate-based clotting assay using factor VII-
depleted plasma. Shown is the quantity of rFVIIa in cell lysates expressed as percentage of control. Data represents the mean with error bars indicat-
ing SEM (n = 3). **P ≤ 001, compared to control (-) by one-way analysis of variance with Dunnett’s post-test. (D) Immunofluorescent staining of
MEG-01 cells under the experimental conditions described in panel C. Staining details are given in the legend of Fig 1D. rFVIIa is stained in green,
nuclei in blue, and the cell membrane is represented by the dotted line. Scale bars indicate 20 lm. Original magnification 6309. ab, antibody.
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the lag time of the thrombin generation curve in normal,
FVII-, and FVIII-depleted plasma, compared to addition of
PLPs generated from MEG-01 cells that had not been
exposed to rFVIIa (Fig 1F). rFVIIa-containing PLPs also had
a slight but significantly increased peak thrombin generation
compared to control PLPs (Fig 1G). Whether rFVIIa in PLPs
does not encounter inhibitors (such as tissue factor pathway
inhibitor and antithrombin) or whether the rFVIIa measured
in our assay only represents a fraction of total rFVIIa in
PLPs, with the remainder being in complex with an inhibi-
tor, requires further study.
We next assessed the mechanism of uptake of rFVIIa by
MEG-01 cells. We hypothesized a role for negatively charged
phospholipids, glycoprotein (GP)Iba and endothelial protein
C receptor (EPCR), which are all known binding partners for
rFVIIa (Lisman & de Groot, 2015). GPIba was hardly
detected on the surface of differentiated MEG-01 cells:
25%  06% [(mean  SD, n = 3) of cells stained positive
for GPIba, Fig 2A]. In contrast, EPCR was abundantly pre-
sent on MEG-01 cells with 732%  118% (mean  SD,
n = 3) of cells staining positive (Fig 2B), which has, to our
knowledge, not been reported before. Uptake of rFVIIa was
not affected by Annexin A5, excluding a role for negatively
charged phospholipids in rFVIIa uptake, but a 760%  87%
[mean  SD] reduction of rFVIIa uptake was observed in the
presence of an antibody to EPCR (Fig 2C). Immunofluores-
cent staining of rFVIIa confirmed these results (Fig 2D).
EPCR appears to fulfil multiple critical features in the mode
of action of rFVIIa, including enhancement of haemostatic
activity in the intravascular space (Pavani et al, 2014),
improvement of endothelial barrier function (Sundaram et al,
2014), transport of rFVIIa to extravascular sites (Clark et al,
2012) and uptake by megakaryocytes in the bone marrow
(this study).
Taken together, we demonstrate EPCR-dependent uptake
of rFVIIa by megakaryocytes with subsequent production of
rFVIIa-containing ‘prohaemostatic’ platelets. Whether this
mechanism acts in vivo requires further study, but delayed
generation of rFVIIa-containing platelets appears a plausible
mechanism to partly explain the efficacy of once-daily rFVIIa
prophylaxis in inhibitor-complicated haemophilia.
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Autoimmune thrombotic thrombocytopenic purpura associated
with HHV8-related Multicentric Castleman disease
Thrombotic thrombocytopenic purpura (TTP) is a throm-
botic microangiopathy (TMA) that results from severe
ADAMTS13 (A Disintegrin And Metalloprotease with
Thrombospondin type 1 motif member 13) deficiency. The
main cause of TTP is autoantibodies against ADAMTS13
(Furlan et al, 1998; Tsai & Lian, 1998).
Multicentric Castleman disease (MCD) is a rare lympho-
proliferative disorder, marked by recurrent flares of fever,
lymphadenopathy and splenomegaly. MCD presents with
cytopenias and elevated C reactive-protein (CRP). MCD is
more frequent in association with human immunodefi-
ciency virus (HIV) infection. Human herpes virus 8
(HHV8) is responsible for the onset of MCD (HHV8/
MCD) in all HIV-associated MCD (HIV/MCD) and in half
of HIV negative patients (Soulier et al, 1995; Oksenhendler
et al, 1996).
Several autoimmune diseases have been associated with
MCD (Muskardin et al, 2012). We report for the first time
four cases of TTP associated with HHV8/MCD.
All the patients included in a prospective database for
Castleman disease between 1 January 2003 and 1 October
2012 who presented with a TMA were included in this study.
Patients’ records were reviewed using a pre-established chart.
Thrombotic thrombocytopenic purpura was defined by
TMA and severe ADAMTS13 deficiency (<5% of normal
activity). ADAMTS13 activity and anti-ADAMTS13
Table I. Characteristics of patients at TMA onset
Patient 1 Patient 2 Patient 3 Patient 4 Median
Age (years) 56 44 52 42 48
Sex Male Male Male Male
HIV (years since diagnosis) * 46 113 134 1128
CD4 cell count (x 109/l) (1562) 0538 0252 0313 0313§
HIV viral load (copies/ml) * 300 48 397
Haemoglobin (g/l) 78 72 55 39 635
Reticulocyte count (x 109/l) 77 15 70 17 435
Platelet count (x 109/l) 3 22 18 10 14
Schizocytes + + + +
Creatinine (lmol/l) 180 177 193 76 178,5
LDH (u/l) 1800 1453 1600 2000 1700
CRP (mg/l) 80 85 81 333 83
HHV8 RT-PCR (copies/ml) 77,359 10,111 +† 151,189 77,359
ADAMTS13 (%activity) <5% <5% <5% <5% <5%
Anti-ADAMTS13 antibodies (u/ml) >100 84 74 70 79
Histological examination Left axillary LAD
consistent with
HHV8/MCD and KS
Infraclavicular LAD
consistent with
HHV8/MCD without KS
Inguinal LAD consistent
with HHV8/MCD and
TMA without KS
NA
KS (years since diagnosis) Yes (26) Yes‡ No No
TMA, thrombotic microangiopathy; MCD, Multicentric Castleman disease; HIV, Human Immunodeficiency Virus; CRP, C-Reactive Protein;
HHV8, Human Herpes Virus 8; RT-PCR, Real Time Polymerase Chain Reaction; ADAMTS13, A Disintegrin And Metalloprotease with Throm-
bospondin type 1 motif member 13; KS, Kaposi Sarcoma; LAD, Lymphadenopathy, NA, Not available.
*Not appropriate (HIV negative).
†Testing performed at another institution using qualitative PCR.
‡Diagnosis was concomitant with TMA.
§Patient 1 (HIV negative) not included.
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